You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
君实生物-B(01877.HK)拟与苏州信诺维医药签署《联合用药临床研究合作协议》
格隆汇 07-31 22:06

格隆汇7月31日丨君实生物-B(01877.HK)公告,公司拟与苏州信诺维医药科技有限公司签署《联合用药临床研究合作协议》。根据协议约定,信诺维拟作为申办方在中国大陆(不包括香港、澳门和台湾地区)地区开展公司产品特瑞普利单抗与信诺维产品XNW7201治疗消化道肿瘤(包括食道癌、胃癌和结直肠癌)的联合用药临床试验。

协议的签署,将进一步拓展公司产品特瑞普利单抗所针对的适应症,深化公司临床布局,对公司发展将产生积极影响,不存在损害公司及股东利益的情形。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account